Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 683 results

Media Release / Jan 04, 2018

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

- Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal…
Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Media Release / Dec 18, 2017

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)- In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82%…
Media Release / Dec 18, 2017

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Media Release / Dec 11, 2017

Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

- Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN…
Media Release / Dec 11, 2017

Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Media Release / Dec 10, 2017

Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

- At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached- Grade 3/4…
Media Release / Dec 10, 2017

Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Media Release / Dec 07, 2017

Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis

- ASLeap trial to evaluate impact of increasing the dose of Cosentyx (secukinumab) to 300 mg in patients who do not achieve symptom remission after 16 weeks of treatment with the approved dose of 150…

‹ Previous page
1
…
32
33
34
35
36
37
38
…
69
› Next page